Abstract
The mainstay treatment of hepatic encephalopathy (HE) includes lactulose or enulose (poorly absorbed disaccharides) and rifaximin (an antibiotic). Whereas these agents likely act by reducing ammonia production and absorption in the intestine, glycerol phenylbutyrate (GPB) directly lowers ammonia by providing an alternate pathway to urea. Currently approved for the treatment of urea cycle disorders, GPB is now being studied for …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
